Palo Alto Health Sciences Chief Clinical Officer Dr. Robert Cuyler to Present Webinar on Tele-therapy for Mental Health

DANVILLE, Calif., Feb. 10, 2017 /PRNewswire/ -- Palo Alto Health Sciences (PAHS), developer of the Freespira^® in-home treatment for panic and symptoms of panic, today announced that Chief Clinical Officer Dr. Robert Cuyler, PhD will conduct a webinar titled "Optimizing Your Clinical Practice for Tele-Therapy."  The event, which takes place February 23^rd, is provided by the Anxiety and Depression Association of America (ADAA), a professional society serving mental health care treatment providers.

"Tele-therapy is an emerging modality that enables mental health professionals to provide treatment to patients who have difficultly consistently coming to the office for face-to-face therapy," said Dr. Cuyler, who has extensively studied telemedicine for over a decade.  PAHS CEO, Debra Reisenthel, added: "Dr. Cuyler is a recognized pioneer in the field of telemedicine and we are pleased that ADAA has invited him to present this webinar.  We also believe that Freespira, because it is an in-home treatment, is particularly well-suited for tele-therapy."

Mental health providers can learn more and register for Dr. Cuyler's presentation at https://www.adaa.org/resources-professionals/conference-education/professional-webinars#teletherapy

About Palo Alto Health Sciences, Inc. and Freespira
Palo Alto Health Sciences, Inc. is a privately held Silicon Valley company at the forefront of revolutionizing behavioral healthcare with evidence-based, non-invasive, drug-free solutions. The Company's first product, Freespira, is an FDA-cleared treatment for individuals suffering from panic attacks and other symptoms of panic. In the United States, over 6.7 million adults annually suffer from Panic Disorder; panic attacks affect a total of 27 million adults in the U.S. every year and are a common component of other anxiety disorders. Patients with panic disorder often chronically hyperventilate, even when not experiencing a panic attack, and this abnormal breathing pattern has been shown to exacerbate attacks. Freespira works by training the patient to stabilize their respiration rate and reduce hyperventilation.  Over the course of treatment, Freespira eliminates or reduces the symptoms of panic and panic attacks.  Freespira is commercially available throughout the U.S. and therapists are successfully treating patients with outstanding results, even in the most severe cases. To learn more, visit http://www.freespira.com or contact [email protected].

SOURCE Palo Alto Health Sciences

Related Links

http://freespira.com